The present invention is concerned with compounds of the general Formula
I: 1
and pharmaceutically acceptable salts thereof, which are useful as melanin
concentrating hormone receptor antagonists, particularly MCH-1R
antagonists. As such, compounds of the present invention are useful for
the treatment or prevention of obesity or eating disorders associated
with excessive food intake and complications thereof, osteoarthritis,
certain cancers, AIDS wasting, cachexia, frailty (particularly in
elderly), mental disorders stress, cognitive disorders, sexual function,
reproductive function, kidney function, locomotor disorders, attention
deficit disorder (ADD), substance abuse disorders and dyskinesias,
Huntington's disease, epilepsy, memory function, and spinal muscular
atrophy. Compounds of formula I may therefore be used in the treatment of
these conditions, and in the manufacture of a medicament useful in
treating these conditions. Pharmaceutical formulations comprising one of
the compounds of formula (I) as an active ingredient are disclosed, as
are processes for preparing these compounds.
